ATC Group: A03FA Propulsives

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A03FA in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A03 Drugs for functional gastrointestinal disorders
3 A03F Propulsives
4 A03FA Propulsives

Group A03FA contents

Code Title
A03FA01 Metoclopramide
A03FA02 Cisapride
A03FA03 Domperidone
A03FA04 Bromopride
A03FA05 Alizapride
A03FA06 Clebopride

Active ingredients in A03FA

Active Ingredient Description

Alizapride is a dopamine antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting, including postoperative nausea and vomiting. It is structurally related to metoclopramide and other benzamides.


Cinitapride is an agonist of 5-HT4 and 5-HT1 receptors and antagonist of 5-HT2 receptors. Cinitapride is marketed worldwide for the treatment of gastrointestinal disorders related to motility such as indigestion or functional or non-ulcer dyspepsia, gastroesophageal reflux diseases, delay in gastric emptying and vomiting.


Cisapride is a substituted piperidinyl benzamide prokinetic agent. Cisapride facilitates release of acetylcholine from the myenteric plexus, resulting in increased gastrointestinal motility. In addition, cisapride has been found to act as a serotonin agonist, stimulating type 4 receptors, and a serotonin 5-HT3 receptor antagonist.


Clebopride is a dopamine antagonist drug. It is used to treat functional gastrointestinal disorder such as nausea or vomiting. Unchanged parent drug was the most abundant compound in human urine. Major metabolites included the hydroxylation at benzyl group to yield carbinolamine and its further N-dealkylation product, and the piperidine ring hydroxylation/oxidation metabolite (a lactam).


Domperidone is a dopamine antagonist with anti-emetic properties, Domperidone does not readily cross the blood-brain barrier. In domperidone users, especially in adults, extrapyramidal side effects are very rare, but domperidone promotes the release of prolactin from the pituitary.


Itopride activates the gastrointestinal propulsive motility by dopamine D2 receptors antagonistic action and acetylcholine esterase inhibitory action. Itopride activates acetylcholine release and inhibits its degradation.


The action of metoclopramide is closely associated with parasympathetic nervous control of the upper gastro-intestinal tract where it has the effect of encouraging normal peristaltic action. This provides for a fundamental approach to the control of those conditions where disturbed gastrointestinal motility is a common underlying factor.


Related product monographs

Title Information Source Document Type  
CLOPERAN Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
COSTI Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
ELITAN Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
MAXOLON Solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
MAXOLON Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
MOTILIUM Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
PEPTOMET Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
PROGIT Film-coated tablet MPI, EU: SmPC
REGLAN Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
TOPRISAN Film-coated tablet Medicines Authority (MT) MPI, EU: SmPC